Novo Nordisk Falls Over 7% Pre-Market as Wegovy Sales Miss Expectations

TradingKey - On September 21, Novo Nordisk (NVO) fell more than 7% in U.S. pre-market trading at one point. The company's latest earnings report showed that its full-year sales and profit forecasts improved from previous guidance, but sales performance of its core weight-loss drug Wegovy still missed market expectations, becoming the primary factor dragging down the stock price.

Source: TradingView

Novo Nordisk stated that it currently expects the maximum decline in sales and profit this year to be around 6%, significantly better than the previously projected maximum drop of 12%. This adjustment indicates an improved outlook for the company's full-year operating performance, which the market might have otherwise viewed as a positive signal. However, Wegovy's quarterly sales figures missed expectations, sparking fresh investor concerns over the future growth rate of the company's weight-loss drug business.

Data showed that second-quarter Wegovy tablet sales reached 3.22 billion Danish kroner (approximately $494 million), below the market expectation of 3.27 billion Danish kroner, with actual performance slightly missing analysts' estimates. Although the gap was relatively small, because Wegovy has been a major growth driver for Novo Nordisk's weight-loss drug business, the market pays high attention to its sales performance, making even a slight miss prone to triggering stock price volatility.

In recent years, Novo Nordisk has rapidly expanded its obesity drug business with weight-loss products such as Wegovy, becoming a key player in the global weight-loss drug market. As the market size continues to expand, investors have also set higher expectations for Wegovy's sales growth.